OUR PURPOSE

EATRIS is a permanent EU biomedical research infrastructure.

EATRIS accelerates translation of science into medical products that benefit patients and improve human health.

OUR AIMS

1. Improving access to academic expertise
2. Increasing utilisation of academic infrastructure
3. Developing and validating tools that improve pipeline output
4. Facilitating public-private collaboration in research
OUR SCOPE

- Preclinical discovery to clinical proof of concept
- Product platforms: Advanced Therapy Medicinal Products, Small Molecules, Vaccines
- Enabling platforms: Biomarkers, Imaging & Tracing

OUR BENEFITS

1. Risk-free access to evaluate European expertise
2. Multi-site and multi-disciplinary collaboration in Europe
3. Optimising translation with highly specialized expertise, as needed
**GEOGRAPHY**

- **Participating countries:**
  Czech Republic, Estonia, Finland, France, Italy, Luxembourg, The Netherlands, Norway, Spain, Slovenia, Sweden

- **Observer:**
  Latvia

**EATRIS institutes**
90+ academic & non-profit research institutes, including 45 university medical centers covering 200 million patients

**EATRIS financial model and funding**
Non-profit, ERIC legal status with funding provided by: 70% countries, 20% subsidies, 10% matchmaking
EATRIS INTRODUCTION

= translational academic medical centers (45)

NORWAY (3)
- Bergen Institute of Medicine
- Centre for Molecular Medicine Norway
- Oslo University Hospital

NETHERLANDS (9)
- University Medical Center Groningen
- Erasmus University Medical Center
- VU University Medical Center
- Netherlands Cancer Institute
- Radboud University Medical Center
- University Medical Center Utrecht
- Maastricht University Medical Center
- Academic Medical Center Amsterdam
- Leiden University Medical Center

FRANCE (1)
- Albert Chevalier-Henri Mondor Hospital

SPAIN (13)
- Catalan Institute of Oncology (IDIBELL)
- Hospital Clinic of Barcelona (IDIBAPS)
- Hospital/Institute Biodonostia
- University Hospital La Princesa
- Hospital de la Santa Creu i Sant Pau
- Health Research Institute Santiago de Compostela
- Hospital La Paz Institute for Health Research
- INCLIVA Valencia
- Institute of Biomedicine Seville
- University Hospital Ramón y Cajal
- Medical Research Institute of Hospital La Fe
- Vall d’Hebron University Hospital
- Fundación Jiménez Díaz University Hospital

SWEDEN (3)
- Karolinska University Hospital
- Lund University Hospital
- Uppsala University Hospital

FINLAND (3)
- Institute for Molecular Medicine Finland
- Turku University Hospital
- University of Eastern Finland Hospital

ESTONIA (1)
- Tartu University Hospital

CZECH REPUBLIC (2)
- Institute of Molecular and Translational Medicine Olomouc
- Clinical Research Center of St. Anne’s University Hospital Brno

ITALY (10)
- National Cancer Institute, Aviano
- IRCCS National Cancer Institute, Milan
- Ospedale Pediatrico Bambino Gesù
- IRCCS National Cancer Institute Giovanni Paolo II, Bari
- IRCCS National Cancer Institute G. Pascale, Naples
- IRCCS Luigi Maria Monti
- Regena Elena National Cancer Institute
- IRCCS Istituto Ortopedico Galeazzi
- San Raffaele Scientific Institute
- Istituto Superiore di Sanità
EXAMPLES OF CURRENT PROJECTS

1. 5-site immune-inflammation imaging hub for GSK: imaging biomarker validation
2. 3-site 89Zr antibody imaging hub for UCB: imaging of antibodies and biologicals
3. Single-site primate 89Zr antibody imaging for international Japanese pharma
4. Translation Together: NCATS, AMED, TIA, CDRD, focus on reproducibility, translation

EXAMPLES OF PROJECTS IN DEVELOPMENT

1. EANM EARL accreditation for 89Zr PET-CT imaging, with 10-14 sites in pilot
2. INFRADEV3
3. H2020 CAR-T, cell tracking/imaging, coordinated by Mangala Srinivas (RadboudUMC) – 4+ countries, 8 institutes, 3-4 SMEs, GE Healthcare, HESI, 1-2 large pharma
Contact

Tim Moser
Industry Partnering Specialist
timmoser@eatris.eu

Toni Andreu
Scientific Director
toniandreu@eatris.eu